Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus
Open Access
- 1 April 2009
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 296 (4), R1282-R1289
- https://doi.org/10.1152/ajpregu.90992.2008
Abstract
Women with systemic lupus erythematosus (SLE) exhibit a high prevalence of hypertension and renal injury. Rosiglitazone (Rosi), a peroxisome proliferator activator receptor gamma (PPARγ) agonist, has renal protective and antihypertensive effects. We tested whether Rosi ameliorates hypertension and renal injury in a female mouse model of SLE (NZBWF1). Thirty-week-old SLE and control (NZW/LacJ) mice ( n ≥ 6/group) were fed Rosi (5 mg·kg−1·day−1in standard chow) or standard chow for 4 wk. SLE mice had increased blood pressure (BP in mmHg) compared with controls (139 ± 4 vs. 111 ± 4, P < 0.05). Rosi treatment lowered BP in SLE mice (127 ± 4, P < 0.05) but not in controls (111 ± 4). Urinary albumin (μg/mg creatinine) was increased in SLE mice compared with controls (12,396 ± 6,525 vs. 50 ± 6) and reduced with Rosi treatment (148 ± 117). Glomerulosclerosis (% of glomeruli with sclerosis) was reduced in Rosi-treated SLE mice (4.2 ± 1.6 vs. 0.4 ± 0.3, P < 0.05). Renal monocyte/macrophage numbers (cell number/1,320 points counted) were reduced in SLE mice treated with Rosi (32.6 ± 11.0 vs. 10.6 ± 3.6, P < 0.05) but unchanged in controls (3.7 ± 1.6 vs. 3.7 ± 2.0). Renal osteopontin expression, a cytokine-regulating macrophage recruitment, was reduced in Rosi-treated SLE mice. Urinary endothelin (in pg/mg creatinine) was increased in SLE mice compared with controls (1.9 ± 0.59 vs. 0.6 ± 0.04, P < 0.05) and reduced in SLE mice treated with Rosi (0.8 ± 0.11, P < 0.05). PPARγ protein expression in the renal cortex was significantly lower in SLE mice compared with controls and was unaffected by Rosi. These data suggest that Rosi may be an important therapeutic option for the treatment of SLE hypertension and renal injury.Keywords
This publication has 64 references indexed in Scilit:
- PPARs in Alzheimer's DiseasePPAR Research, 2008
- Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)Cardiovascular Diabetology, 2008
- TNF-α inhibition reduces renal injury in DOCA-salt hypertensive ratsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2008
- Synergistic vascular protective effects of combined low doses of PPARα and PPARγ activators in angiotensin II-induced hypertension in ratsBritish Journal of Pharmacology, 2007
- Present concepts and future outlook: Function of peroxisome proliferator‐activated receptors (PPARs) for pathogenesis, progression, and therapy of cancerJournal of Cellular Physiology, 2007
- Endothelin A Receptor Blockade Reduces Diabetic Renal Injury via an Anti-Inflammatory MechanismJournal of the American Society of Nephrology, 2007
- Role of Endothelin in Mediating Tumor Necrosis Factor-Induced Hypertension in Pregnant RatsHypertension, 2005
- Clinical and histopathological progression of lesions in lupus-prone (NZB×NZW) F1 miceExperimental and Toxicologic Pathology, 2004
- Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHRLife Sciences, 1997
- Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus.Annals Of The Rheumatic Diseases, 1995